Valneva SE (VALN) Cash & Equivalents (2019 - 2026)
Valneva SE (VALN) posted Cash & Equivalents of $123.2 million for Q1 2026, down 3.45% sequentially from $127.6 million in Q4 2025, and down 23.42% YoY from $160.9 million in Q1 2025.
Analysis
Valneva SE (VALN) Cash & Equivalents (2019 - 2026) Analysis & Trends
Valneva SE has reported Cash & Equivalents for 8 years, with the latest figure at $123.2 million in Q1 2026.
- Quarterly Cash & Equivalents fell 23.42% year-over-year to $123.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $123.2 million (down 23.42% YoY) and the FY2025 annual result came in at $127.6 million, down 29.92% from the prior year.
- Cash & Equivalents declined to $123.2 million in Q1 2026 per VALN's latest filing, from $127.6 million in the prior quarter.
- Over five years, Cash & Equivalents peaked at $358.8 million in Q2 2022 and troughed at $123.2 million in Q1 2026.
- A 5-year average of $207.6 million and a median of $182.6 million in 2025 frame the typical range for Cash & Equivalents.
- The sharpest annual moves came in 2022 and 2023: Cash & Equivalents surged 638756.95% in 2022, then tumbled 53.6% in 2023.
- Over 5 years, Cash & Equivalents stood at $292.3 million in 2022, then sank by 53.6% to $135.7 million in 2023, then surged by 32.55% to $179.8 million in 2024, then dropped by 29.02% to $127.6 million in 2025, then dropped by 3.45% to $123.2 million in 2026.
- According to Business Quant data, Cash & Equivalents over the past three periods registered $123.2 million, $127.6 million, and $167.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | 3.58 Bn |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | 1.72 Bn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | 815.44 Mn |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | 5.10 Bn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | 1.71 Bn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | 811.99 Mn |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Valneva SE | 580.64 Mn | 439.38 Mn | 1.86 Mn | 141.26 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 141.26 Mn |
| Mar 31, 2026 | 123.24 Mn |
| Dec 31, 2025 | 127.64 Mn |
| Sep 30, 2025 | 167.71 Mn |
| Jun 30, 2025 | 182.59 Mn |
| Mar 31, 2025 | 160.93 Mn |
| Dec 31, 2024 | 179.81 Mn |
| Sep 30, 2024 | 171.69 Mn |
| Jun 30, 2024 | 141.52 Mn |
| Mar 31, 2024 | 191.89 Mn |
| Dec 31, 2023 | 135.65 Mn |
| Sep 30, 2023 | 186.42 Mn |
| Jun 30, 2023 | 222.59 Mn |
| Mar 31, 2023 | 273.15 Mn |
| Dec 31, 2022 | 292.33 Mn |
| Sep 30, 2022 | 263.20 Mn |
| Jun 30, 2022 | 358.77 Mn |
| Mar 31, 2022 | 349.34 Mn |
| Dec 31, 2021 | 45,758.84 |
| Sep 30, 2021 | 292.40 Mn |